Thus, the restoration of p53 function remains an important objective for treating human cancers with wild-type TP53. A popular approach has been to inhibit Mdm2, the main ubiquitin E3 ligase that normally binds p53 and downregulates its function6. Here, MDM2 is linked to cancer.